Bli medlem
Bli medlem

Du är här


PRA Health Sciences: PRA Health Sciences Named International Clinical Research Company of the Year

RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc.,
(PRA) (NASDAQ:PRAH) is pleased to announce that for the third consecutive
year it was recognized as the Clinical Research Company of the Year. PRA
received the award at the PharmaTimes International Clinical Researcher of
the Year ceremony in London. This award follows PRA's recent recognition as
Clinical Research Company of the Year in the PharmaTimes Americas competition
where PRA captured six individual awards, including two gold (Experienced CRA
and Strategic Partnership-PRA and CytRx).

A photo accompanying this announcement is available at

"PRA is honored to receive this prestigious recognition," said Sean Leech,
Executive Vice President, Product Registration (Europe, Asia Pacific and
Africa). "This award speaks to the passion and professionalism PRA employees
bring to their clinical development work. We are extremely proud of this

PRA also swept the Clinical Trial Administrator category winning gold, silver
and bronze awards. Individual gold award recipients include:

* Clinical Trial Administrator: Irina Teslenko (Spain)
* Project Manager: Petra Croon (Belgium)
* Strategic Partnership Team (PRA and Bayer): Nicole Duffey (US), Kish Khan

Organized by PharmaTimes, the annual International Clinical Researcher of the
Year competition provides a unique opportunity for clinical researchers from
all over the world to benchmark their competencies and skills against their
peers in an international learning environment. Designed and judged by an
independent steering committee of high-level industry leaders, the
International Clinical Researcher of the Year has categories for clinical
researchers and teams at all stages of their career.


PRA is one of the world's leading global contract research organizations, by
revenue, providing outsourced clinical development services to the
biotechnology and pharmaceutical industries. PRA's global clinical
development platform includes approximately 70 offices across North America,
Europe, Asia, Latin America, South Africa, Australia and the Middle East, and
approximately 12,000 employees worldwide. Since 2000, PRA has performed
approximately 3,300 clinical trials worldwide and has worked on more than 100
marketed drugs across several therapeutic areas. In addition, PRA has
participated in the pivotal or supportive trials that led to U.S. Food and
Drug Administration or international regulatory approval of more than 60
drugs. To learn more about PRA, please visit

PRA Health Sciences, Inc.
Christine Rogers


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PRA Health Sciences via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.